Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline

Coronary Heart Disease: full-pipeline trial registry

3 of 20 indexed Coronary Heart Disease trials are currently recruiting.

Corpus placement: #848 of 28,707 conditions by registered trial count.

20 US clinical trials · 3 currently recruiting · #848 of 28,707 conditions by registered trial count

Coronary Heart Disease: 20 US clinical trials tracked, 3 recruiting.

Coronary Heart Disease is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is CardioDx, running 2 of these trials.

Enrollment posture brief

Registry condition coronary-heart-disease

OPEN 3 | RECR 15% | LATE 5 | EARLY 4 | RANK #848 | SPON 2

Nearest open-share peer: Recurrent Adult Acute Myeloid Leukemia (15% recruiting · 20 trials)

Advanced or Metastatic Solid55%ALS50%Abdominal Pain25%Acute Myocardial Infarction25%Coronary Heart Disease (this)15%
Open-enrollment share among volume-matched conditions near Coronary Heart Disease

Coronary Heart Disease lists 3 open slots (15% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Coronary Heart Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Coronary Heart Disease is recruiting below its size-band peers.

    3 of 20 indexed trials (15%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Coronary Heart Disease trials is spread across many organizations.

    CardioDx accounts for 2 of 20 trials (10%). 18 distinct sponsors appear on at least one study for this condition label.

  3. Typical Coronary Heart Disease enrolment sits around 489 participants.

    Median target enrolment is 489 among the 20 trials that report a genuine target (sentinel values excluded). 7 of those (35%) plan for fewer than 100 participants.

  4. Coronary Heart Disease research is mostly interventional.

    18 interventional and 2 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23Phase 34Phase 41

Open and recent trials

20 total, page 1 of 1

RECRUITING NA 500 participants

Project 3: ACHIEVE- CHD

University Hospitals Cleveland Medical Center

NCT05918380

RECRUITING NA 95 participants

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

West Virginia School of Osteopathic Medicine

NCT06049420

RECRUITING Early Phase 1 52 participants

Thiamine Intervention and Coronary Artery Bypass Grafting

University of California, Los Angeles

NCT06326996

COMPLETED Phase 3 15,871 participants

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Hoffmann-La Roche

NCT00658515

COMPLETED 4,350 participants

Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree

CardioDx

NCT00500617

COMPLETED Phase 3 1,743 participants

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

AstraZeneca

NCT00525824

COMPLETED Phase 3 1,445 participants

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

Abbott

NCT00300482

COMPLETED Phase 4 1,000 participants

Cholesterol and Pharmacogenetic Study

UCSF Benioff Children's Hospital Oakland

NCT00451828

COMPLETED Phase 3 682 participants

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

AbbVie (prior sponsor, Abbott)

NCT00616772

COMPLETED 581 participants

Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)

CardioDx

NCT01117506

COMPLETED Phase 2 534 participants

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

Daiichi Sankyo

NCT00185042

COMPLETED NA 489 participants

Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk

University of North Carolina, Chapel Hill

NCT01245686

COMPLETED NA 361 participants

An IT Approach to Implementing Depression Treatment in Cardiac Patients (iHeart DepCare)

Columbia University

NCT03882411

COMPLETED NA 338 participants

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

Beth Israel Deaconess Medical Center

NCT01624727

COMPLETED Phase 2 130 participants

A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease

Hoffmann-La Roche

NCT00655473

COMPLETED Phase 2 31 participants

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Novartis Pharmaceuticals

NCT06097663

COMPLETED NA 26 participants

Walnut Consumption, Endothelial Function, and Biomarkers

Brigham and Women's Hospital

NCT01884363

COMPLETED NA 22 participants

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

University of Florida

NCT00379808

COMPLETED NA 20 participants

Developing and Evaluating an Indoor Air Pollution Intervention Among Cardiovascular Patients: the AIRWISE Study

University of Montana

NCT06384625

COMPLETED NA 5 participants

Relationship Between the Menstrual Cycle and Heart Disease in Women

Oregon Health and Science University

NCT01546454

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 4
Phase 4 1

Named interventions

Most-linked intervention names on Coronary Heart Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
6 trials
Corus CAD (ASGES) Diagnostic test
2 trials
Dalcetrapib (RO4607381) Drug
2 trials
ABT-335 Drug
2 trials
Simvastatin Drug
2 trials
Lifestyle and medication intervention Behavioral
1 trials
AIRWISE Other
1 trials
Ethinyl Estradiol-Levonorgestrel combination Drug
1 trials

US sites by state

Facility locations filed on Coronary Heart Disease trials. A trial with sites in several states counts in each.

California 6 trials
Tennessee 3 trials
North Carolina 3 trials
Missouri 3 trials
Florida 3 trials
Colorado 3 trials
Arizona 3 trials
Pennsylvania 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Coronary Heart Disease page

20 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Coronary Heart Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • CardioDx sponsors the most Coronary Heart Disease trials on record, review their full trial history before evaluating a specific study. See CardioDx's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Heart Disease condition card totals 20 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.